Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 2016/7 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients (i.e., second– and later lines)—PD-L1 inhibitor Tecentriq (Roche/Genentech/Chugai) followed by PD-1 inhibitor Opdivo (Bristol-Myers Squibb) and other PD-1/PD-L1 inhibitors—significant sales are forecast for the unresectable locally advanced or metastatic setting. There is now intense Phase II/III pipeline activity, with some drugs in the late-phase pipeline also targeting previously untreated unresectable locally advanced or metastatic bladder cancer (i.e., first-line setting). We anticipate that several new therapies will gain approvals within the forecast period, resulting in increased therapy options.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Already a Client? Log in to access this report.
Laura Vinuesa, DVM, is a Senior Business Insights Analyst in the Oncology Division at Decision Resources Group, with expertise in thyroid carcinoma and bladder cancer. Previously, Dr. Vinuesa was an EU Market Access Analyst in the Global Market Access Insights Team at Decision Resources Group. She has expertise in market access, pricing and reimbursement, health technology assessment, and health policy. Prior to joining Decision Resources, she worked as Market Access & Institutional Relations Analyst at Pfizer in Spain, providing support for the successful market launch of drugs for different areas: cardiovascular, oncology, mental disorder and rare disease. She is a Doctor of Veterinary Medicine from the Complutense University of Madrid, and holds a in Clinical Research and Pharmaceutical Medicine from EPHOS - School of PharmaStudies. lvinuesa@
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.
is a business insights analyst in the oncology team at Decision Resources Group. Ms. Mitchell previously worked as an analyst at financial PR firm, Tulchan Communications, where she provided news on the pharmaceutical sector from a commercial perspective. Prior to this, Ms. Mitchell was a project assistant within the consulting team at DRG-Abacus where she learnt about HEOR and market access. Ms. Mitchell obtained her Masters in Cancer Sciences from the University of Birmingham. The degree focused on the expression of immune checkpoints in DLBCL. She also holds a in Biomedical Science from the University of Reading.